Metrion Biosciences and Assay.Works Partner to Enhance Ion Channel Drug Discovery
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and Assay.Works GmbH (Assay.Works), experts in assay development and High Throughput Screening (HTS) services, today announced a collaboration that will significantly expand the companies’ range of ion channel drug discovery services.
The agreement gives Metrion access to Assay.Works extensive knowledge of HTS and assay validation technologies, including 384 well format screening and compound handling facilities, a library of 74,000 small molecules and a catalogue of ‘assay.ready’ cell lines for use in primary screening and selectivity assays.
Assay.Works clients will in turn be able to access Metrion’s extensive ion channel target know-how, electrophysiology based assay services, CiPA compliant cardiac safety profiling, and expanding range of phenotypic and translational assays in the cardiac and neuroscience fields.
HTS approaches to drug discovery can be valuable when novel starting points for chemistry are not readily available or when a rapid screen of a knowledge-based selection of compounds is required. Combining HTS with high quality compound libraries facilitates the identification of unique and tractable starting points for drug discovery programmes. Plate-based selectivity assays are also useful adjuncts to electrophysiology-based profiling, and can be added where appropriate in the screening cascade.
Dr Andrew Southan, Head of Commercial Operations at Metrion Biosciences said: “We look forward to working with the Assay.Works team, who share Metrion’s collaborative approach to client programmes. Providing access to Assay.Works’ outstanding expertise in plate-based assay development and optimisation, this partnership enables Metrion to offer clients ion channel drug discovery programmes starting at the HTS stage.”
Dr Ralf Schwandner, Founder and CEO, Assay.Works, commented: “We are excited to partner with the exceptional team of scientists at Metrion Biosciences. Having worked on multiple ion channel programs, we understand the challenge of generating meaningful and reproducible results at a reasonable throughput for this important drug target class. Accessing Metrion Biosciences' expertise in ion channel research and electrophysiology will allow us to offer our clients a broad range of assay services for ion channel drug discovery.”
This article has been republished from materials provided by Metrion. Note: material may have been edited for length and content. For further information, please contact the cited source.
T Cells Attack and Kill Dopamine-Producing Cells in Parkinson's diseaseNews
Researchers in Germany discover a potential new target for treating Parkinson's diseaseREAD MORE
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE